Skip to main content

CORRECTION article

Front. Cardiovasc. Med. , 19 January 2023

Sec. Cardio-Oncology

Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1129873

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

This article is a correction to:

  1. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

    1. Read original article
\nVincenzo Quagliariello Vincenzo Quagliariello1*Margherita Passariello,Margherita Passariello2,3Annabella Di MauroAnnabella Di Mauro4Ciro CipulloCiro Cipullo4Andrea PacconeAndrea Paccone1Antonio BarbieriAntonio Barbieri5Giuseppe PalmaGiuseppe Palma5Antonio LucianoAntonio Luciano5Simona BuccoloSimona Buccolo1Irma BiscegliaIrma Bisceglia6Maria Laura CanaleMaria Laura Canale7Giuseppina GallucciGiuseppina Gallucci8Alessandro InnoAlessandro Inno9Claudia De Lorenzo,Claudia De Lorenzo2,3Nicola Maurea Nicola Maurea1*
  • 1Division of Cardiology, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)- Fondazione G. Pascale, Naples, Italy
  • 2Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
  • 3Ceinge-Biotecnologie Avanzate s.c.a.r.l., Naples, Italy
  • 4Pathology Unit, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)- Fondazione G. Pascale, Naples, Italy
  • 5Animal Facility, Istituto Nazionale Tumori- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)- Fondazione G. Pascale, Naples, Italy
  • 6Servizi Cardiologici Integrati, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
  • 7U.O.C. Cardiologia, Ospedale Versilia, Lido di Camaiore (LU), Camaiore, Italy
  • 8Cardiologia, Centro di Riferimento Oncologico della Basilicata (CROB) - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rionero in Vulture, Italy
  • 9Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Negrar, Italy

A corrigendum on
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

by Quagliariello, V., Passariello, M., Di Mauro, A., Cipullo, C., Paccone, A., Barbieri, A., Palma, G., Luciano, A., Buccolo, S., Bisceglia, I., Canale, M. L., Gallucci, G., Inno, A., De Lorenzo, C., and Maurea, N. (2022). Front. Cardiovasc. Med. 9:930797. doi: 10.3389/fcvm.2022.930797

In the published article, there was an error in the Data Availability statement. The original statement incorrectly read: “The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.” The correct Data Availability statement appears below:

“The data presented in the study are deposited in the Zenodo repository, accession number https://zenodo.org/record/7040431#.YyMLcYrP1D9.”

In the published article, there was an error in the Funding statement. The original statement incorrectly read: “This work was funded by a Ricerca Corrente grant from the Italian Ministry of Health.” The correct Funding statement appears below:

“This work was funded by a “Ricerca Corrente” grant from the Italian Ministry of Health titled “Cardiotossicità da chemioterapie, targeted therapies e immunoterapie, diagnosi precoce e cardioprotezione, Ricerca preclinica e clinica”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: immunotherapy, biomarkers, preclinical study, mechanisms, inflammation, interleukin

Citation: Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C and Maurea N (2023) Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front. Cardiovasc. Med. 10:1129873. doi: 10.3389/fcvm.2023.1129873

Received: 22 December 2022; Accepted: 05 January 2023;
Published: 19 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Quagliariello, Passariello, Di Mauro, Cipullo, Paccone, Barbieri, Palma, Luciano, Buccolo, Bisceglia, Canale, Gallucci, Inno, De Lorenzo and Maurea. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Vincenzo Quagliariello, yes cXVhZ2xpYXJpZWxsby5lbnpvQGdtYWlsLmNvbQ==; Nicola Maurea, yes bi5tYXVyZWFAaXN0aXR1dG90dW1vcmkubmEuaXQ=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more